Banner
Uk.ResellerClub Launches New Promotion Offering Free .CO.UK Domains With Hosting Packages

LONDON, May 10, 2013 /PRNewswire/ --  Web Presence products provider Uk.ResellerClub have...

Wirecard Gains SriLankan Airlines As A New Customer In Asia

MUNICH, Germany, April 30, 2013 /PRNewswire/ -- Wirecard AG, provider of a globally accepted payment...

Global Payments Continues Focus On Mobile Payments In The UK

LONDON, March 28, 2013 /PRNewswire/ -- Global Payments is further strengthening its mobile payment...

Induced Pluripotent Stem Cell Industry Report

Stem cell research and experimentation has been in process for well over five decades and they...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll


GBI Research, a business intelligence provider, has released its latest research, 'Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar', which provides insights into bone metabolic disease therapeutics until 2018.  


Hundreds of millions of people in the world suffer from allergies, and it is estimated that 300 million have asthma. In some countries, one in three children has asthma, and 80% of them also have other allergies. There are many guidelines and consensus documents about how to treat this disease but the dissemination and implementation of these are still major challenges. 


Life-threatening allergic reactions in children, such as anaphylaxis, have increased 7-fold in the last decade and a third of all allergic shocks in children occur for the first time at school with teachers largely unprepared.


Two studies in Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed. 

 The group led by Alberto Bardelli, Ph.D., of the University of Torino, Italy describes the development of secondary resistance mutations to the anti-EGFR monoclonal antibody cetuximab (Erbitux(R)) in patients with metastatic colorectal cancer (mCRC) [Misale S. et al., Nature Epub 13 June 2012].The second group led by Luis Diaz, MD and Bert Vogelstein, M.D. from Johns Hopkins University reached similar conclusions after studying mCRC patients treated with a monotherapy of panitumumab (Vectibix(R)) [Diaz Jr LA et al., Nature Epub 13 June 2012]. 


Results Presented at the 17th Congress of the European Hematology Association by Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., said six-year follow-up results from a Phase 3 randomized, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R) (imatinib). 

The six-year data shows progression-free survival of 49.3% and an overall survival of 71% for patients randomized to dasatinib 100 mg once daily (n=167), with 6% of patients (n=10) progressing to accelerated or blast phase on study at six years of follow-up.[1]